Global ENT Disorder Treatment Market 2020-2024

耳鼻咽喉科(ENT)疾患治療の世界市場:鼻炎、副鼻腔炎、中耳炎、扁桃炎

◆タイトル:Global ENT Disorder Treatment Market 2020-2024
◆商品コード:IRTNTR40834
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2020年1月10日
◆ページ数:120
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他の地域
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートは耳鼻咽喉科(ENT)疾患治療の世界市場について調査・分析し、エグゼクティブサマリー、レポート範囲、市場環境、市場規模、ファイブフォース分析、顧客状況、疾患別(鼻炎、副鼻腔炎、中耳炎、扁桃炎)分析、地域別状況、意思決定フレームワーク、市場の要因・課題、市場トレンド、企業状況、企業分析などを含め、次の構成でお届けいたします。
・エグゼクティブサマリ
・レポート範囲
・市場環境
・市場規模
・ファイブフォース分析
・顧客状況
・耳鼻咽喉科(ENT)疾患治療の世界市場:疾患別(鼻炎、副鼻腔炎、中耳炎、扁桃炎)
・地域別状況
・意思決定フレームワーク
・市場の要因・課題
・市場トレンド
・企業状況
・企業分析

Global ENT Disorder Treatment Market 2020-2024
Technavio has been monitoring the global ent disorder treatment market and it is poised to grow by USD 2.1 bn during 2020-2024, progressing at a CAGR of 2% during the forecast period. Our reports on global ent disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rapid environmental deterioration resulting in several allergic conditions.In addition, advances in research on allergic disorders is anticipated to boost the growth of the global ent disorder treatment market as well.

Market Segmentation
Technavio’s global ent disorder treatment market is segmented as below:
Indication:
• Rhinitis
• Sinusitis
• Otitis Media
• Tonsillitis

Geographic Segmentation:
• Asia
• Europe
• North America
• ROW

Key Trends for global ent disorder treatment market growth
This study identifies advances in research on allergic disorders as the prime reasons driving the global ent disorder treatment market growth during the next few years.

Prominent vendors in global ent disorder treatment market
We provide a detailed analysis of around 25 vendors operating in the global ent disorder treatment market , including some of the vendors such as AbbVie Inc., ALK-Abelló AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc. and Sanofi. .
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit - https://www.technavio.com/report/ent-disorder-treatment-market-industry-analysis

About Technavio
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
o 2.1 Preface
o 2.2 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
o Market ecosystem
o Market characteristics
o Market segmentation analysis
PART 04: MARKET SIZING
o Market definition
o Market sizing 2019
o Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY INDICATION
o Market segmentation by indication
o Comparison by indication
o Rhinitis – Market size and forecast 2019-2024
o Sinusitis – Market size and forecast 2019-2024
o Otitis media – Market size and forecast 2019-2024
o Tonsillitis – Market size and forecast 2019-2024
o Market opportunity by indication
PART 08: GEOGRAPHIC LANDSCAPE
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2019-2024
o Europe – Market size and forecast 2019-2024
o Asia – Market size and forecast 2019-2024
o ROW – Market size and forecast 2019-2024
o Key leading countries
o Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
o Market drivers
o Market challenges
PART 11: MARKET TRENDS
o Growing awareness among people about ENT disorder treatment
o Strategic mergers and acquisitions
o Advances in research on allergic disorders
PART 12: VENDOR LANDSCAPE
o Overview
o Landscape disruption
o Competitive scenario
PART 13: VENDOR ANALYSIS
o Vendors covered
o Vendor classification
o Market positioning of vendors
o AbbVie Inc.
o ALK-Abelló AS
o Bayer AG
o Covis Pharma BV
o F. Hoffmann-La Roche Ltd.
o GlaxoSmithKline Plc
o Johnson & Johnson
o Merck & Co., Inc.
o Pfizer Inc.
o Sanofi
PART 14: APPENDIX
o Research methodology
o List of abbreviations
o Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Vendor key offerings
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Customer landscape
Exhibit 19: Indication – Market share 2019-2024 (%)
Exhibit 20: Comparison by indication
Exhibit 21: Rhinitis – Market size and forecast 2019-2024 ($ millions)
Exhibit 22: Brief description of types of rhinitis
Exhibit 23: Rhinitis – Year-over-year growth 2020-2024 (%)
Exhibit 24: Sinusitis – Market size and forecast 2019-2024 ($ millions)
Exhibit 25: Brief description of types of sinusitis
Exhibit 26: Sinusitis – Year-over-year growth 2020-2024 (%)
Exhibit 27: Otitis media – Market size and forecast 2019-2024 ($ millions)
Exhibit 28: Otitis media – Year-over-year growth 2020-2024 (%)
Exhibit 29: Tonsillitis – Market size and forecast 2019-2024 ($ millions)
Exhibit 30: Tonsillitis – Year-over-year growth 2020-2024 (%)
Exhibit 31: Market opportunity by indication
Exhibit 32: Market share by geography 2019-2024 (%)
Exhibit 33: Geographic comparison
Exhibit 34: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 35: North America – Year-over-year growth 2020-2024 (%)
Exhibit 36: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 37: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 38: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 39: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 40: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 41: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Growth of geriatric population 2009-2018 (%)
Exhibit 45: Overlapping symptoms of ENT disorders
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: AbbVie Inc. – Vendor overview
Exhibit 53: AbbVie Inc. – Business segments
Exhibit 54: AbbVie Inc. – Organizational developments
Exhibit 55: AbbVie Inc. – Geographic focus
Exhibit 56: AbbVie Inc. – Key offerings
Exhibit 57: ALK-Abelló AS – Vendor overview
Exhibit 58: ALK-Abelló AS – Business segments
Exhibit 59: ALK-Abelló AS – Geographic focus
Exhibit 60: ALK-Abelló AS – Key offerings
Exhibit 61: Bayer AG – Vendor overview
Exhibit 62: Bayer AG – Business segments
Exhibit 63: Bayer AG – Organizational developments
Exhibit 64: Bayer AG – Geographic focus
Exhibit 65: Bayer AG – Segment focus
Exhibit 66: Bayer AG – Key offerings
Exhibit 67: Covis Pharma BV – Vendor overview
Exhibit 68: Covis Pharma BV – Business segments
Exhibit 69: Covis Pharma BV – Organizational developments
Exhibit 70: Covis Pharma BV – Key offerings
Exhibit 71: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 72: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 73: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 74: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 75: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 76: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 77: GlaxoSmithKline Plc – Vendor overview
Exhibit 78: GlaxoSmithKline Plc – Business segments
Exhibit 79: GlaxoSmithKline Plc – Organizational developments
Exhibit 80: GlaxoSmithKline Plc – Geographic focus
Exhibit 81: GlaxoSmithKline Plc – Segment focus
Exhibit 82: GlaxoSmithKline Plc – Key offerings
Exhibit 83: Johnson & Johnson – Vendor overview
Exhibit 84: Johnson & Johnson – Business segments
Exhibit 85: Johnson & Johnson – Organizational developments
Exhibit 86: Johnson & Johnson – Geographic focus
Exhibit 87: Johnson & Johnson – Segment focus
Exhibit 88: Johnson & Johnson – Key offerings
Exhibit 89: Merck & Co. Inc. – Vendor overview
Exhibit 90: Merck & Co. Inc. – Business segments
Exhibit 91: Merck & Co. Inc. – Organizational developments
Exhibit 92: Merck & Co. Inc. – Geographic focus
Exhibit 93: Merck & Co. Inc. – Segment focus
Exhibit 94: Merck & Co. Inc. – Key offerings
Exhibit 95: Pfizer Inc. – Vendor overview
Exhibit 96: Pfizer Inc. – Business segments
Exhibit 97: Pfizer Inc. – Organizational developments
Exhibit 98: Pfizer Inc. – Geographic focus
Exhibit 99: Pfizer Inc. – Segment focus
Exhibit 100: Pfizer Inc. – Key offerings
Exhibit 101: Sanofi – Vendor overview
Exhibit 102: Sanofi – Business segments
Exhibit 103: Sanofi – Organizational developments
Exhibit 104: Sanofi – Geographic focus
Exhibit 105: Sanofi – Segment focus
Exhibit 106: Sanofi – Key offerings
Exhibit 107: Validation techniques employed for market sizing
Exhibit 108: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc., ALK-Abelló AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[耳鼻咽喉科(ENT)疾患治療の世界市場:鼻炎、副鼻腔炎、中耳炎、扁桃炎]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆